Qiagen (NYSE:QGEN) Sees Strong Trading Volume – Time to Buy?

Qiagen N.V. (NYSE:QGEN) saw an uptick in trading volume on Tuesday. 6,199,460 shares changed hands during trading, an increase of 152% from the previous session’s volume of 2,460,511 shares. The stock last traded at $49.3870 and had previously closed at $46.55.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover offer is the main catalyst. EQT has agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share for all outstanding shares. The proposal confirms earlier reports that EQT was in advanced discussions and gives investors a potential cash-exit value. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Preliminary Q3 results were solid. Qiagen reported preliminary net sales of $548 million and adjusted diluted EPS of $0.65, both at reported and constant exchange rates. The results indicate continued operating resilience ahead of the company’s full Q3 report scheduled for November 4, 2026. QIAGEN reports preliminary Q3 2026 results
• Positive Sentiment: Robert W. Baird raised its target. Baird increased its Qiagen price target from $50 to $52 and maintained an “outperform” rating, signaling further potential upside if the transaction does not fully determine the share price. Baird raises Qiagen price target
• Neutral Sentiment: The takeover now shifts attention from fundamentals to deal completion. Investors will likely focus on shareholder, regulatory and other closing conditions, as well as whether the proposed consideration represents the final value available to shareholders.
• Negative Sentiment: Transaction risk remains. Until the EQT acquisition closes, Qiagen remains exposed to potential delays, revised terms or failure to complete the deal. The takeover also limits the near-term importance of older standalone valuation estimates, including the previously reported brokerage consensus target of $43.93.

Analyst Ratings Changes

A number of brokerages have recently issued reports on QGEN. Robert W. Baird increased their price target on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 11th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $44.68.

Qiagen Price Performance

The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock has a market capitalization of $10.31 billion, a PE ratio of 25.63, a P/E/G ratio of 4.87 and a beta of 0.61. The company’s fifty day simple moving average is $44.15 and its two-hundred day simple moving average is $40.51.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, sell-side analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. increased its position in Qiagen by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after buying an additional 286 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after acquiring an additional 317 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Qiagen by 46.8% in the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after acquiring an additional 876 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Qiagen by 2.4% in the third quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock valued at $1,938,000 after acquiring an additional 1,003 shares in the last quarter. Finally, Hilltop National Bank purchased a new stake in shares of Qiagen in the second quarter valued at $50,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.